Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Total Liabilities (2019 - 2025)

Cellebrite DI has reported Total Liabilities over the past 7 years, most recently at $454.5 million for Q4 2025.

  • Quarterly results put Total Liabilities at $454.5 million for Q4 2025, up 28.2% from a year ago — trailing twelve months through Dec 2025 was $454.5 million (up 28.2% YoY), and the annual figure for FY2025 was $454.5 million, up 28.2%.
  • Total Liabilities for Q4 2025 was $454.5 million at Cellebrite DI, up from $354.5 million in the prior quarter.
  • Over the last five years, Total Liabilities for CLBT hit a ceiling of $498.7 million in Q4 2023 and a floor of $329.4 million in Q4 2022.
  • Median Total Liabilities over the past 5 years was $413.1 million (2021), compared with a mean of $410.1 million.
  • Biggest five-year swings in Total Liabilities: soared 107.21% in 2021 and later fell 28.9% in 2024.
  • Cellebrite DI's Total Liabilities stood at $413.1 million in 2021, then fell by 20.26% to $329.4 million in 2022, then skyrocketed by 51.38% to $498.7 million in 2023, then fell by 28.9% to $354.5 million in 2024, then rose by 28.2% to $454.5 million in 2025.
  • The last three reported values for Total Liabilities were $454.5 million (Q4 2025), $354.5 million (Q4 2024), and $498.7 million (Q4 2023) per Business Quant data.